Liver Transplantation for Pediatric Liver Cancer

Unresectable hepatocellular carcinoma (HCC) was first removed successfully with total hepatectomy and liver transplantation (LT) in a child over five decades ago. Since then, children with unresectable liver cancer have benefitted greatly from LT and a confluence of several equally important endeavors. Regional and trans-continental collaborations have accelerated the development and standardization of chemotherapy regimens, which provide disease control to enable LT, and also serve as a test of unresectability. In the process, tumor histology, imaging protocols, and tumor staging have also matured to better assess response and LT candidacy. Significant trends include a steady increase in the incidence of and use of LT for hepatoblastoma, and a significant improvement in survival after LT for HCC with each decade. Although LT is curative for most unresectable primary liver sarcomas, such as embryonal sarcoma, the malignant rhabdoid tumor appears relapse-prone despite chemotherapy and LT. Pediatric liver tumors remain rare, and diagnostic uncertainty in some settings can potentially delay treatment or lead to the selection of less effective chemotherapy. We review the current knowledge relevant to diagnosis, LT candidacy, and post-transplant outcomes for these tumors, emphasizing recent observations made from large registries or larger series.

[1]  R. Alaggio,et al.  Hepatoblastoma and Pediatric Hepatocellular Carcinoma: An Update , 2020, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[2]  Yanming Zhou,et al.  Long‐term survival outcomes of undifferentiated embryonal sarcoma of the liver: a pooled analysis of 308 patients , 2020, ANZ journal of surgery.

[3]  A. Mehrabi,et al.  Incidence trends and survival prediction of hepatoblastoma in children: a population-based study , 2019, Cancer communications.

[4]  G. Chavhan,et al.  Rare malignant liver tumors in children , 2019, Pediatric Radiology.

[5]  Zhishui Chen,et al.  Assessment of Survival of Pediatric Patients With Hepatoblastoma Who Received Chemotherapy Following Liver Transplant or Liver Resection , 2019, JAMA network open.

[6]  S. Plon,et al.  Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation , 2019, Pediatric blood & cancer.

[7]  Tania A Desrosiers,et al.  Association Between Birth Defects and Cancer Risk Among Children and Adolescents in a Population-Based Assessment of 10 Million Live Births. , 2019, JAMA oncology.

[8]  J. Neglia,et al.  Success of chemotherapy and a liver transplant in a pediatric patient with hepatic angiosarcoma: A case report , 2019, Pediatric transplantation.

[9]  U. Tannuri,et al.  Extensive Hepatectomy as an Alternative to Liver Transplant in Advanced Hepatoblastoma: A New Protocol Used in a Pediatric Liver Transplantation Center. , 2019, Transplantation proceedings.

[10]  C. Rodríguez-Galindo,et al.  Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. , 2019, The Lancet. Oncology.

[11]  G. Tiao,et al.  Hepatoblastoma—The Evolution of Biology, Surgery, and Transplantation , 2018, Children.

[12]  P. Schroder,et al.  Improved contemporary outcomes of liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma , 2018, Pediatric transplantation.

[13]  N. Girard,et al.  Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy , 2018, Nature Reviews Clinical Oncology.

[14]  A. Ferrari,et al.  Biliary tract rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Associazione Italiana Ematologia Oncologia Pediatrica , 2018, Tumori.

[15]  R. Scolyer,et al.  Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies , 2018, JAMA oncology.

[16]  Michael C. Heinold,et al.  The landscape of genomic alterations across childhood cancers , 2018, Nature.

[17]  B. Morland,et al.  2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT) , 2018, Pediatric Radiology.

[18]  Xin Zhou,et al.  Pan-cancer genome and transcriptome analyses of 1,699 pediatric leukemias and solid tumors , 2018, Nature.

[19]  V. Ng,et al.  Extreme hepatic resections for the treatment of advanced hepatoblastoma: Are planned close margins an acceptable approach? , 2018, Pediatric blood & cancer.

[20]  P. Stephens,et al.  General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study. , 2017, Human pathology.

[21]  G. Mazariegos,et al.  Pediatric liver transplantation for hepatocellular cancer and rare liver malignancies: US multicenter and single‐center experience (1981‐2015) , 2017, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[22]  C. Van Waes,et al.  Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma , 2017, Cancer Immunology Research.

[23]  Darjus F. Tschaharganeh,et al.  DNAJB1–PRKACA fusion kinase interacts with β-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma , 2017, Proceedings of the National Academy of Sciences.

[24]  M. Fischer,et al.  A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors , 2017, Clinical Cancer Research.

[25]  S. Rosenberg,et al.  'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations , 2017, Nature Immunology.

[26]  D. V. von Schweinitz,et al.  Pediatric hepatocellular carcinoma: challenges and solutions , 2017, Journal of hepatocellular carcinoma.

[27]  A. Schenk,et al.  Computer-assisted surgery planning in children with complex liver tumors identifies variability of the classical Couinaud classification. , 2016, Journal of pediatric surgery.

[28]  B. Morland,et al.  Hepatocellular Carcinoma in Children: Does Modified Platinum- and Doxorubicin-Based Chemotherapy Increase Tumor Resectability and Change Outcome? Lessons Learned From the SIOPEL 2 and 3 Studies. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Q. Dong,et al.  Usefulness of three-dimensional(3D) simulation software in hepatectomy for pediatric hepatoblastoma. , 2016, Surgical oncology.

[30]  K. McHugh,et al.  MRI of paediatric liver tumours: How we review and report , 2016, Cancer Imaging.

[31]  L. Zitvogel,et al.  Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.

[32]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[33]  I. Endo,et al.  Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): short-term outcome, functional changes in the future liver remnant, and tumor growth activity. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[34]  Haifeng Xu,et al.  Value of Quantitative and Qualitative Analyses of Circulating Cell-Free DNA as Diagnostic Tools for Hepatocellular Carcinoma , 2015, Medicine.

[35]  T. Strom,et al.  The genomic landscape of hepatoblastoma and their progenies with HCC-like features. , 2014, Journal of hepatology.

[36]  Hongyang Wang,et al.  Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex , 2014, Hepatology.

[37]  P. Adusumilli,et al.  Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence , 2014, Clinical Cancer Research.

[38]  M. Georgieff,et al.  Congenital abnormalities and hepatoblastoma: A report from the Children's Oncology Group (COG) and the Utah Population Database (UPDB) , 2014, American journal of medical genetics. Part A.

[39]  F. Alvarez,et al.  A child with unresectable biliary rhabdomyosarcoma: 48‐month disease‐free survival after liver transplantation , 2014, Pediatric transplantation.

[40]  M. Finegold,et al.  Angiosarcoma successfully treated with liver transplantation and sirolimus , 2014, Pediatric transplantation.

[41]  Yukichi Tanaka,et al.  Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium , 2014, Modern Pathology.

[42]  V. Vacic,et al.  Detection of a Recurrent DNAJB1-PRKACA Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma , 2014, Science.

[43]  B. Morland,et al.  Rejection is less common in children undergoing liver transplantation for hepatoblastoma , 2014, Pediatric transplantation.

[44]  G. Tiao,et al.  Multimodal therapy including liver transplantation for hepatic undifferentiated embryonal sarcoma , 2014, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[45]  M. Quaglia State of the art in oncology: high risk neuroblastoma, alveolar rhabdomyosarcoma, desmoplastic small round cell tumor, and POST-TEXT 3 and 4 hepatoblastoma. , 2014 .

[46]  K. Gow,et al.  Surgical treatment of primary liver tumors in children: Outcomes analysis of resection and transplantation in the SEER database , 2013, Pediatric transplantation.

[47]  R. Busuttil,et al.  A Single-institution Retrospective Cases Series of Childhood Undifferentiated Embryonal Liver Sarcoma (UELS): Success of Combined Therapy and the Use of Orthotopic Liver Transplant , 2013, Journal of pediatric hematology/oncology.

[48]  B. Morland,et al.  Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study , 2013, The Lancet. Oncology.

[49]  F. Pruvot,et al.  Liver Transplantation for Neuroendocrine Tumors in Europe—Results and Trends in Patient Selection: A 213-Case European Liver Transplant Registry Study , 2013, Annals of surgery.

[50]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[51]  A. Burroughs,et al.  Hepatic Hemangiosarcoma: An Absolute Contraindication to Liver Transplantation—The European Liver Transplant Registry Experience , 2013, Transplantation.

[52]  G. Mazariegos,et al.  Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: new trends and future opportunities. , 2013, Surgery.

[53]  S. Nadalin,et al.  ALPPS in Right Trisectionectomy: a Safe Procedure to Avoid Postoperative Liver Failure? , 2013, Journal of Gastrointestinal Surgery.

[54]  B. Morland,et al.  Prognostic stratification for children with hepatoblastoma: the SIOPEL experience. , 2012, European journal of cancer.

[55]  J. Feusner,et al.  Rhabdoid tumors of the liver: Rare, aggressive, and poorly responsive to standard cytotoxic chemotherapy , 2011, Pediatric blood & cancer.

[56]  D. Dominique,et al.  The Widening Spectrum of Liver Angiosarcoma in Children , 2011 .

[57]  R. Superina,et al.  Successful nontransplant resection of POST‐TEXT III and IV hepatoblastoma , 2011, Cancer.

[58]  N. Gupta,et al.  Undifferentiated Embryonal Sarcoma of the Liver is Associated with Mesenchymal Hamartoma and Multiple Chromosomal Abnormalities: A Review of Eleven Cases , 2011, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[59]  J. Otte,et al.  PLUTO First report , 2010, Pediatric transplantation.

[60]  G. Perilongo,et al.  Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  J. Otte,et al.  The role of liver transplantation for pediatric epithelioid hemangioendothelioma , 2010, Pediatric transplantation.

[62]  J. Goss,et al.  Pediatric liver transplantation for primary malignant liver tumors with a focus on hepatic epithelioid hemangioendothelioma: The UNOS experience , 2010, Pediatric transplantation.

[63]  M. Rela,et al.  Liver transplantation for hepatoblastoma , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[64]  L. Zitvogel,et al.  The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.

[65]  V. Mazzaferro,et al.  The Place of Liver Transplantation in the Treatment of Hepatic Epitheloid Hemangioendothelioma: Report of the European Liver Transplant Registry , 2007, Annals of surgery.

[66]  K. McHugh,et al.  2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group , 2006, Pediatric Radiology.

[67]  B. Pollock,et al.  The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds. , 2005, The Journal of pediatrics.

[68]  S. Ranganathan,et al.  β-Catenin and Met Deregulation in Childhood Hepatoblastomas , 2005 .

[69]  J. Biegel,et al.  Immunohistochemical Analysis of hSNF5/INI1 Distinguishes Renal and Extra-renal Malignant Rhabdoid Tumors From Other Pediatric Soft Tissue Tumors , 2004, The American journal of surgical pathology.

[70]  J. Biegel,et al.  Immunohistochemical Analysis of hSNF5/INI1 in Pediatric CNS Neoplasms , 2004, The American journal of surgical pathology.

[71]  P. Ramani,et al.  Management of hepatic epithelioid haemangio-endothelioma in children: what option? , 2004, British Journal of Cancer.

[72]  G. Perilongo,et al.  Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2. , 2004, European journal of cancer.

[73]  G. Perilongo,et al.  Liver transplantation for hepatoblastoma: Results from the International Society of Pediatric Oncology (SIOP) study SIOPEL‐1 and review of the world experience , 2004, Pediatric blood & cancer.

[74]  J. Quinn,et al.  Abstracts reprinted from Journal of Clinical Oncology , 2002, Annals of Surgical Oncology.

[75]  G. Perilongo,et al.  Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  J. Quinn,et al.  Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  M. Tucker,et al.  Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. , 1998, The Journal of pediatrics.

[78]  J. Quinn,et al.  The surgical management of children with incompletely resected hepatic cancer is facilitated by intensive chemotherapy. , 1991, Journal of pediatric surgery.

[79]  T. Starzl,et al.  The many faces of multivisceral transplantation. , 1991, Surgery, gynecology & obstetrics.

[80]  T. Starzl,et al.  Liver transplantation for hepatoblastoma. The American experience. , 1991, Annals of surgery.

[81]  T. Starzl,et al.  Abdominal Organ Cluster Transplantation for the Treatment of Upper Abdominal Malignancies , 1989, Annals of surgery.

[82]  J. Mann,et al.  Association between hepatoblastoma and polyposis coli. , 1983, Archives of disease in childhood.

[83]  M. Finegold,et al.  Primary hepatic tumors of childhood. , 1983, Human pathology.

[84]  T. Starzl,et al.  Orthotopic liver transplantation in ninety-three patients. , 1976, Surgery, gynecology & obstetrics.

[85]  T. Starzl,et al.  Orthotopic homotransplantation of the human liver. , 1968 .

[86]  F. Dagher,et al.  IMMUNOSUPPRESSION AND VASCULAR INSUFFICIENCY IN LIVER TRANSPLANTATION * , 1965 .

[87]  T. Starzl,et al.  IMMUNOSUPPRESSION AFTER EXPERIMENTAL AND CLINICAL HOMOTRANSPLANTATION OF THE LIVER. , 1964, Annals of surgery.

[88]  Demirleau,et al.  [ATTEMPTED HEPATIC HOMOGRAFT]. , 1964, Memoires. Academie de chirurgie.

[89]  T. Starzl,et al.  HOMOTRANSPLANTATION OF THE LIVER IN HUMANS. , 1963, Surgery, gynecology & obstetrics.

[90]  K. Dong,et al.  Liver Transplantation for Biliary Rhabdomyosarcoma With Liver Metastasis: Report of One Case. , 2017, Transplantation proceedings.

[91]  Yukichi Tanaka,et al.  Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. , 2017, The Lancet. Oncology.

[92]  M. L. La Quaglia State of the art in oncology: high risk neuroblastoma, alveolar rhabdomyosarcoma, desmoplastic small round cell tumor, and POST-TEXT 3 and 4 hepatoblastoma. , 2014, Journal of pediatric surgery.

[93]  S. Ranganathan,et al.  beta-Catenin and met deregulation in childhood Hepatoblastomas. , 2005, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[94]  P. Voûte,et al.  Half-life of alpha-fetoprotein in patients with a teratoma, endodermal sinus tumor, or hepatoblastoma. , 1988, Pediatric hematology and oncology.

[95]  M. Shipp,et al.  Effective cisplatin (DDP) based chemotherapy in the treatment of hepatoblastoma. , 1985, Medical and pediatric oncology.